The Experts below are selected from a list of 243 Experts worldwide ranked by ideXlab platform
John T Mullen - One of the best experts on this subject based on the ideXlab platform.
-
retroperitoneal sarcoma rps high risk gross tumor volume boost hr gtv boost contour delineation agreement among nrg sarcoma radiation and Surgical Oncologists
Annals of Surgical Oncology, 2015Co-Authors: Elizabeth H. Baldini, Ross Allen Abrams, Kilian E. Salerno, Ivy A. Petersen, Chandrajit P Raut, Yen-lin Chen, John M Kane, Curtiland Deville, Walter R Bosch, John T MullenAbstract:Purpose Curative intent management of retroperitoneal sarcoma (RPS) requires gross total resection. Preoperative radiotherapy (RT) often is used as an adjuvant to surgery, but recurrence rates remain high. To enhance RT efficacy with acceptable tolerance, there is interest in delivering “boost doses” of RT to high-risk areas of gross tumor volume (HR GTV) judged to be at risk for positive resection margins. We sought to evaluate variability in HR GTV boost target volume delineation among collaborating sarcoma radiation and Surgical Oncologist teams.
-
Retroperitoneal Sarcoma (RPS) High Risk Gross Tumor Volume Boost (HR GTV Boost) Contour Delineation Agreement Among NRG Sarcoma Radiation and Surgical Oncologists
Annals of Surgical Oncology, 2015Co-Authors: Elizabeth H. Baldini, Ross Allen Abrams, Kilian E. Salerno, Ivy A. Petersen, Chandrajit P Raut, Yen-lin Chen, Walter Bosch, John M Kane, Curtiland Deville, John T MullenAbstract:PURPOSE: Curative intent management of retroperitoneal sarcoma (RPS) requires gross total resection. Preoperative radiotherapy (RT) often is used as an adjuvant to surgery, but recurrence rates remain high. To enhance RT efficacy with acceptable tolerance, there is interest in delivering "boost doses" of RT to high-risk areas of gross tumor volume (HR GTV) judged to be at risk for positive resection margins. We sought to evaluate variability in HR GTV boost target volume delineation among collaborating sarcoma radiation and Surgical Oncologist teams. METHODS: Radiation planning CT scans for three cases of RPS were distributed to seven paired radiation and Surgical Oncologist teams at six institutions. Teams contoured HR GTV boost volumes for each case. Analysis of contour agreement was performed using the simultaneous truth and performance level estimation (STAPLE) algorithm and kappa statistics. RESULTS: HRGTV boost volume contour agreement between the seven teams was "substantial" or "moderate" for all cases. Agreement was best on the torso wall posteriorly (abutting posterior chest abdominal wall) and medially (abutting ipsilateral para-vertebral space and great vessels). Contours varied more significantly abutting visceral organs due to differing Surgical opinions regarding planned partial organ resection. CONCLUSIONS: Agreement of RPS HRGTV boost volumes between sarcoma radiation and Surgical Oncologist teams was substantial to moderate. Differences were most striking in regions abutting visceral organs, highlighting the importance of collaboration between the radiation and Surgical Oncologist for "individualized" target delineation on the basis of areas deemed at risk and planned resection.
Elizabeth H. Baldini - One of the best experts on this subject based on the ideXlab platform.
-
retroperitoneal sarcoma rps high risk gross tumor volume boost hr gtv boost contour delineation agreement among nrg sarcoma radiation and Surgical Oncologists
Annals of Surgical Oncology, 2015Co-Authors: Elizabeth H. Baldini, Ross Allen Abrams, Kilian E. Salerno, Ivy A. Petersen, Chandrajit P Raut, Yen-lin Chen, John M Kane, Curtiland Deville, Walter R Bosch, John T MullenAbstract:Purpose Curative intent management of retroperitoneal sarcoma (RPS) requires gross total resection. Preoperative radiotherapy (RT) often is used as an adjuvant to surgery, but recurrence rates remain high. To enhance RT efficacy with acceptable tolerance, there is interest in delivering “boost doses” of RT to high-risk areas of gross tumor volume (HR GTV) judged to be at risk for positive resection margins. We sought to evaluate variability in HR GTV boost target volume delineation among collaborating sarcoma radiation and Surgical Oncologist teams.
-
Retroperitoneal Sarcoma (RPS) High Risk Gross Tumor Volume Boost (HR GTV Boost) Contour Delineation Agreement Among NRG Sarcoma Radiation and Surgical Oncologists
Annals of Surgical Oncology, 2015Co-Authors: Elizabeth H. Baldini, Ross Allen Abrams, Kilian E. Salerno, Ivy A. Petersen, Chandrajit P Raut, Yen-lin Chen, Walter Bosch, John M Kane, Curtiland Deville, John T MullenAbstract:PURPOSE: Curative intent management of retroperitoneal sarcoma (RPS) requires gross total resection. Preoperative radiotherapy (RT) often is used as an adjuvant to surgery, but recurrence rates remain high. To enhance RT efficacy with acceptable tolerance, there is interest in delivering "boost doses" of RT to high-risk areas of gross tumor volume (HR GTV) judged to be at risk for positive resection margins. We sought to evaluate variability in HR GTV boost target volume delineation among collaborating sarcoma radiation and Surgical Oncologist teams. METHODS: Radiation planning CT scans for three cases of RPS were distributed to seven paired radiation and Surgical Oncologist teams at six institutions. Teams contoured HR GTV boost volumes for each case. Analysis of contour agreement was performed using the simultaneous truth and performance level estimation (STAPLE) algorithm and kappa statistics. RESULTS: HRGTV boost volume contour agreement between the seven teams was "substantial" or "moderate" for all cases. Agreement was best on the torso wall posteriorly (abutting posterior chest abdominal wall) and medially (abutting ipsilateral para-vertebral space and great vessels). Contours varied more significantly abutting visceral organs due to differing Surgical opinions regarding planned partial organ resection. CONCLUSIONS: Agreement of RPS HRGTV boost volumes between sarcoma radiation and Surgical Oncologist teams was substantial to moderate. Differences were most striking in regions abutting visceral organs, highlighting the importance of collaboration between the radiation and Surgical Oncologist for "individualized" target delineation on the basis of areas deemed at risk and planned resection.
Charles M. Balch - One of the best experts on this subject based on the ideXlab platform.
-
Joining forces for children with cancer in Latin America
2020Co-Authors: Charles M. Balch, Graeme J. PostonAbstract:Several other countries (including many low-income and middle-income countries, eg, India) have formal Surgical oncology fellowship programmes but the presence of such structured training pathways is not globally uniform. What diff erentiates Surgical oncology from other areas of surgery is the oncology training and expertise needed to address all aspects of cancer management in a multidisciplinary fashion. Thus, the Surgical Oncologist is an Oncologist who performs surgery but can also incorporate advances in oncology management into the treatment plan of their Surgical patient with cancer. 6,7 Hence, the training requirements for Surgical Oncologists should refl ect what is expected of them in practice. We hope that the proposed curriculum 2,3
-
Special Article Celebrating SSO 80th Anniversary: William Stewart MacComb—The Father of the Society of Surgical Oncology (SSO) and a Pioneering Surgical Oncologist
Annals of Surgical Oncology, 2020Co-Authors: Charles M. BalchAbstract:The year 2020 marks the 80th anniversary of the Society of Surgical Oncology (SSO), so it is appropriate to celebrate the vision and leadership of Dr. William MacComb, who led the formation of the James Ewing Society as an alumni organization of the Memorial Hospital in New York City. The Ewing Society was later renamed and reorganized as the SSO in 1975. Dr. MacComb was elected as the first and second President of the James Ewing Society from 1940 to 1942. He was elected onto the Executive Council when it first formed in 1947 as the Secretary/Treasurer from 1947 to 1948, as Vice-President from 1948 to 1949, and then continued as a member of the Executive Council for 3 years until 1952. He was elected again as Vice President from 1958 to 1959, as President-elect from 1959 to 1960, as President for a third time from 1960 to 1961, and then as Chair of the Executive Committee from 1961 to 1962. No other person in the history of the SSO was President for multiple terms and also was one of the founding leaders. For these reasons, it would be a fitting accolade to refer to Dr. William MacComb as “the Father of the Society of Surgical Oncology” (founded as the James Ewing Society). Dr. MacComb also served as President of both the American Radium Society (1950) and the Society of Head and Neck Surgery (1969). He one of the first Surgical Oncologist trained in head and neck surgery, and, uniquely, one of the first physicians to be Board Certified in Radiology because of his training and publications in therapeutic radiology. Dr. MacComb made important contributions in the field of Head and Neck surgery, as a pioneer in the development of radiation therapy and radiation physics, and for advancing the use of combined surgery and radiation therapy for head and neck cancers.
-
special article celebrating sso 80th anniversary william stewart maccomb the father of the society of Surgical oncology sso and a pioneering Surgical Oncologist
Annals of Surgical Oncology, 2020Co-Authors: Charles M. BalchAbstract:The year 2020 marks the 80th anniversary of the Society of Surgical Oncology (SSO), so it is appropriate to celebrate the vision and leadership of Dr. William MacComb, who led the formation of the James Ewing Society as an alumni organization of the Memorial Hospital in New York City. The Ewing Society was later renamed and reorganized as the SSO in 1975. Dr. MacComb was elected as the first and second President of the James Ewing Society from 1940 to 1942. He was elected onto the Executive Council when it first formed in 1947 as the Secretary/Treasurer from 1947 to 1948, as Vice-President from 1948 to 1949, and then continued as a member of the Executive Council for 3 years until 1952. He was elected again as Vice President from 1958 to 1959, as President-elect from 1959 to 1960, as President for a third time from 1960 to 1961, and then as Chair of the Executive Committee from 1961 to 1962. No other person in the history of the SSO was President for multiple terms and also was one of the founding leaders. For these reasons, it would be a fitting accolade to refer to Dr. William MacComb as “the Father of the Society of Surgical Oncology” (founded as the James Ewing Society). Dr. MacComb also served as President of both the American Radium Society (1950) and the Society of Head and Neck Surgery (1969). He one of the first Surgical Oncologist trained in head and neck surgery, and, uniquely, one of the first physicians to be Board Certified in Radiology because of his training and publications in therapeutic radiology. Dr. MacComb made important contributions in the field of Head and Neck surgery, as a pioneer in the development of radiation therapy and radiation physics, and for advancing the use of combined surgery and radiation therapy for head and neck cancers.
-
Prescribing patterns of Surgical Oncologists: are we surgeons, Oncologists, or both? Results of a society of Surgical oncology survey.
Annals of Surgical Oncology, 2007Co-Authors: Charles M. BalchAbstract:Although Surgical treatment is the centerpiece of our specialty, what differentiates Surgical oncology from other areas in surgery is the oncology experience and expertise needed in dealing with all aspects of cancer management in a multidisciplinary fashion. ... The salient feature of differentiation is that Surgical oncology is both a technical and cognitive specialty involving a chronic disease process. What is a Surgical Oncologist? Ann Surg Oncol 1993; 1:4 Despite our stated purpose of Surgical oncology as a specialty, it would probably not surprise the readers of the Annals that there is still a fairly widespread perception among medical Oncologists and members of the pharmaceutical companies that ‘‘surgeons spend their time in the operating room and have a relatively minor role in prescribing oncology and supportive drugs.’’ Recently, I talked with a senior marketing executive of a major pharmaceutical company who stated that their company would not advertise in our journal, exhibit at our meeting, or fund SSO educational grants or sponsorships. This was because of their perception that surgeons—including Surgical Oncologists—neither prescribe their drug products nor influence their use in Surgical patients. Perhaps less well understood by both the medical oncology community and the pharmaceutical leadership is that many, if not the majority, of cancer patients look to the surgeon who made the diagnosis and initiated the primary treatment for advice about systemic therapy. Furthermore, Surgical Oncologists have led the way in defining predictors of survival outcomes for the majority of cancers, thereby identifying those at greatest risk of occult distant metastases, and hence are knowledgeable as to which of their Surgical patients might benefit from systemic therapy. While we may know this perception is untrue at an individual level, there is nothing better than having good data to break such molds of misperception. That is why I was pleased with the enormous response from our SSO members to a survey conducted by the Annals of Surgical Oncology Editors and Springer Verlag Publishers. One component of this survey was to tabulate prescribing practice patterns of 532 Surgical Oncologists. This is more than onethird of the active membership and makes the survey results very creditable and representative. (The entire TABLE 1. On average, how many drug orders (inpatient or outpatient) do you or a trainee under your supervision prescribe each week? (520 responses)
Ross Allen Abrams - One of the best experts on this subject based on the ideXlab platform.
-
retroperitoneal sarcoma rps high risk gross tumor volume boost hr gtv boost contour delineation agreement among nrg sarcoma radiation and Surgical Oncologists
Annals of Surgical Oncology, 2015Co-Authors: Elizabeth H. Baldini, Ross Allen Abrams, Kilian E. Salerno, Ivy A. Petersen, Chandrajit P Raut, Yen-lin Chen, John M Kane, Curtiland Deville, Walter R Bosch, John T MullenAbstract:Purpose Curative intent management of retroperitoneal sarcoma (RPS) requires gross total resection. Preoperative radiotherapy (RT) often is used as an adjuvant to surgery, but recurrence rates remain high. To enhance RT efficacy with acceptable tolerance, there is interest in delivering “boost doses” of RT to high-risk areas of gross tumor volume (HR GTV) judged to be at risk for positive resection margins. We sought to evaluate variability in HR GTV boost target volume delineation among collaborating sarcoma radiation and Surgical Oncologist teams.
-
Retroperitoneal Sarcoma (RPS) High Risk Gross Tumor Volume Boost (HR GTV Boost) Contour Delineation Agreement Among NRG Sarcoma Radiation and Surgical Oncologists
Annals of Surgical Oncology, 2015Co-Authors: Elizabeth H. Baldini, Ross Allen Abrams, Kilian E. Salerno, Ivy A. Petersen, Chandrajit P Raut, Yen-lin Chen, Walter Bosch, John M Kane, Curtiland Deville, John T MullenAbstract:PURPOSE: Curative intent management of retroperitoneal sarcoma (RPS) requires gross total resection. Preoperative radiotherapy (RT) often is used as an adjuvant to surgery, but recurrence rates remain high. To enhance RT efficacy with acceptable tolerance, there is interest in delivering "boost doses" of RT to high-risk areas of gross tumor volume (HR GTV) judged to be at risk for positive resection margins. We sought to evaluate variability in HR GTV boost target volume delineation among collaborating sarcoma radiation and Surgical Oncologist teams. METHODS: Radiation planning CT scans for three cases of RPS were distributed to seven paired radiation and Surgical Oncologist teams at six institutions. Teams contoured HR GTV boost volumes for each case. Analysis of contour agreement was performed using the simultaneous truth and performance level estimation (STAPLE) algorithm and kappa statistics. RESULTS: HRGTV boost volume contour agreement between the seven teams was "substantial" or "moderate" for all cases. Agreement was best on the torso wall posteriorly (abutting posterior chest abdominal wall) and medially (abutting ipsilateral para-vertebral space and great vessels). Contours varied more significantly abutting visceral organs due to differing Surgical opinions regarding planned partial organ resection. CONCLUSIONS: Agreement of RPS HRGTV boost volumes between sarcoma radiation and Surgical Oncologist teams was substantial to moderate. Differences were most striking in regions abutting visceral organs, highlighting the importance of collaboration between the radiation and Surgical Oncologist for "individualized" target delineation on the basis of areas deemed at risk and planned resection.
Ivy A. Petersen - One of the best experts on this subject based on the ideXlab platform.
-
retroperitoneal sarcoma rps high risk gross tumor volume boost hr gtv boost contour delineation agreement among nrg sarcoma radiation and Surgical Oncologists
Annals of Surgical Oncology, 2015Co-Authors: Elizabeth H. Baldini, Ross Allen Abrams, Kilian E. Salerno, Ivy A. Petersen, Chandrajit P Raut, Yen-lin Chen, John M Kane, Curtiland Deville, Walter R Bosch, John T MullenAbstract:Purpose Curative intent management of retroperitoneal sarcoma (RPS) requires gross total resection. Preoperative radiotherapy (RT) often is used as an adjuvant to surgery, but recurrence rates remain high. To enhance RT efficacy with acceptable tolerance, there is interest in delivering “boost doses” of RT to high-risk areas of gross tumor volume (HR GTV) judged to be at risk for positive resection margins. We sought to evaluate variability in HR GTV boost target volume delineation among collaborating sarcoma radiation and Surgical Oncologist teams.
-
Retroperitoneal Sarcoma (RPS) High Risk Gross Tumor Volume Boost (HR GTV Boost) Contour Delineation Agreement Among NRG Sarcoma Radiation and Surgical Oncologists
Annals of Surgical Oncology, 2015Co-Authors: Elizabeth H. Baldini, Ross Allen Abrams, Kilian E. Salerno, Ivy A. Petersen, Chandrajit P Raut, Yen-lin Chen, Walter Bosch, John M Kane, Curtiland Deville, John T MullenAbstract:PURPOSE: Curative intent management of retroperitoneal sarcoma (RPS) requires gross total resection. Preoperative radiotherapy (RT) often is used as an adjuvant to surgery, but recurrence rates remain high. To enhance RT efficacy with acceptable tolerance, there is interest in delivering "boost doses" of RT to high-risk areas of gross tumor volume (HR GTV) judged to be at risk for positive resection margins. We sought to evaluate variability in HR GTV boost target volume delineation among collaborating sarcoma radiation and Surgical Oncologist teams. METHODS: Radiation planning CT scans for three cases of RPS were distributed to seven paired radiation and Surgical Oncologist teams at six institutions. Teams contoured HR GTV boost volumes for each case. Analysis of contour agreement was performed using the simultaneous truth and performance level estimation (STAPLE) algorithm and kappa statistics. RESULTS: HRGTV boost volume contour agreement between the seven teams was "substantial" or "moderate" for all cases. Agreement was best on the torso wall posteriorly (abutting posterior chest abdominal wall) and medially (abutting ipsilateral para-vertebral space and great vessels). Contours varied more significantly abutting visceral organs due to differing Surgical opinions regarding planned partial organ resection. CONCLUSIONS: Agreement of RPS HRGTV boost volumes between sarcoma radiation and Surgical Oncologist teams was substantial to moderate. Differences were most striking in regions abutting visceral organs, highlighting the importance of collaboration between the radiation and Surgical Oncologist for "individualized" target delineation on the basis of areas deemed at risk and planned resection.